Renal denervation, a potential deadly decision in the ED, GLP-1 agonists, and an AHA preview are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Renal Denervation
FDA OKs Paradise Renal Denervation System for Hypertension
https://www.medscape.com/viewarticle/998237
- Company Press Release https://www.recormedical.com/recor-medical-and-otsuka-medical-devices-announce-first-fda-approved-renal-denervation-system-for-the-treatment-of-hypertension/
- Six-month Meta-analysis of RDN Studies https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.123.066941
- March This Week in Cardiology with RDN Discussion https://www.medscape.com/viewarticle/989014
II. Potential Deadly Decisions in the ED
Even One Night in the ED Raises Risk for Death
https://www.medscape.com/viewarticle/998080
- JAMA Internal Medicine Study
III. Tirzepatide Approval
FDA Approves Tirzepatide for Treating Obesity
https://www.medscape.com/viewarticle/998225
- SURMOUNT 2 https://doi.org/10.1016/S0140-6736(23)01200-X
- SURMOUNT 1 https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
IV. AHA Preview
Mandrola's Top Trials to Look for at AHA 2023
https://www.medscape.com/viewarticle/998123
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
